Inhibition and possible induction of rat CYP2D after short- and long-term treatment with antidepressants

Journal of Pharmacy and Pharmacology

Volumn 54, Issue 11, 2002, Pages 1545-1552

  Daniel, Władysława A ^a   Haduch, A ^a   Wojcikowski J ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; APOPROTEIN; CLOMIPRAMINE; CYTOCHROME P450 2D; DESIPRAMINE; ETHYLMORPHINE; FLUOXETINE; IMIPRAMINE; MIRTAZAPINE; NEFAZODONE; REACTIVE OXYGEN METABOLITE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; CYTOCHROME P450; ETHYLMORPHINE DEETHYLASE; ETHYLMORPHINE O-DEETHYLASE; ISOENZYME;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; LONG TERM CARE; MALE; NONHUMAN; PROTEIN INTERACTION; RAT; SHORT COURSE THERAPY; ANIMAL; COMPARATIVE STUDY; DRUG EFFECT; KINETICS; METABOLISM; TIME; WISTAR RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; ISOENZYMES; KINETICS; MALE; MICROSOMES, LIVER; RATS; RATS, WISTAR; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 0036847924     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/002235702162     Document Type: Article

References (45)

1. Barbhaiya, R. H., Buch, A. B., Greene, D. S. (1996). Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. Br. J. Pharmacol. 42: 573-581
2. Baum, L. O., Strobel, H. W. (1997) Regulation of expression of cytochrome P-450 2D mRNA in rat brain with steroid hormones. Brain Res. 765: 67-73
3. Bensoussan, C., Delaforge, M., Mansuy, D. (1995) Particular ability of cytochromes P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs. Biochem. Pharmacol. 49: 591-602
4. Bergh, A. F., Strobel, H. W. (1996) Anatomical distribution of NADPH-cytochrome P450 reductase and cytochrome P4502D forms in rat brain: effects of xenobiotics and sex steroids. Mol. Cell. Biochem. 162: 31-41
5. Boobis, A. R., Seddon, C. E., Davies, D. S. (1986) Bufuralol 1′-hydroxylase activity of the rat. Biochem. Pharmacol. 35: 2961-2965
6. Boobis, A. R., Sesardic, D., Murray, B. P., Edwards, R. J., Singleton, A. M., Rich, K. J., Murray, S., de la Torres, R., Seguras, J., Pelkonen, O., Pasanen, M., Kobayashi, S., Zhi-Guang, T., Davies, D. S. (1990) Species variation in the response of the cytochrome P-450-dependent monooxygenase system to inducers and inhibitors. Xenobiotica 20: 1139-1161
7. Brøsen, K., Zeugin, T., Meyer, U. A. (1991) Role of P4502D6, the target of the sparteine-debrisoquine oxidation polymorphism, in the metabolism of imipramine. Clin. Pharmacol. Ther. 49: 609-617
8. Chow, T., Hiroi, T., Imaoka, S., Chiba, K., Funae, Y. (1999a) Isoform-selective metabolism of mianserin by cytochrome P-450 2D. Drug Metab. Dispos. 27: 1200-1204
9. Chow, T., Imaoka, S., Hiroi, T., Funae, Y. (1996b) Developmental changes in the catalytic activity and expression of CYP2D isoforms in the rat liver. Drug Metab. Dispos. 27: 188-192
10. Coutts, R. T., Su, P., Baker, G. B. (1994) Involvement of CYP2D6, CYP3A4, and other cytochromes P450 isoenzymes in N-dealkylation reactions. J. Pharmacol. Toxicol. Methods 31: 177-186
11. Crewee, H. K., Lennard, M. S., Tucker, G. T., Woods, F. R., Haddock, R. E. (1992) The effect of selective re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br. J. Clin. Pharmacol. 34: 262-265
12. Daniel, W., Netter, K. J. (1992) Alteration of cytochrome P-450 by prolonged administration of imipramine and/or lithium to rats. Naunyn Schmiedebergs Arch. Pharmacol. 342: 234-240
13. Daniel, W.A., Syrek, M., Haduch, A., Wójcikowski, J. (1999) The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro studies. Exp. Toxicol. Pathol. 51: 309-314
14. Fonne-Pfister, R., Bargetzi, M. J., Meyer, U. A. (1987) MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isoenzymes (P450buf1, P450db1) catalyzing debrisoquine 4-hydroxylation. Biochem. Biophys. Res. Commun. 148: 1144-1150
15. Glare, P. A., Walsh, T. D., Pippenger, C. E. (1991) A simple, rapid method for the simultaneous determination of morphine and its principal metabolites in plasma using high-performance liquid chromatography and fluorometric detection. Ther. Drug Monit. 13: 226-232
16. Gonzalez, F. J., Skoda, R. C., Kimura, S., Umeno, M., Zanger, U. M., Nebert, D. W., Gelboin, H. V., Hardwick, J. P., Meyer, U. A. (1988) Characterization of the common genetic effect in humans deficient in debrisoquine metabolism. Nature 331: 442-446
17. Hiroi, T., Imaoka, S., Funae, Y. (1998) Dopamine formation from tyramine by CYP2D6. Biochem. Biophys. Res. Commun. 249: 838-843
18. Holm, K. J., Markham, A. (1999) Mirtazapine. A review of its use in major depression. Drugs 57: 607-631
19. Honkakoski, P., Negishi, M. (2000) Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochem. J. 347: 321-337
20. Jeppesen, U., Gram, L. F., Vistisen, K., Loft, S., Poulsen, H. E., Brøsen, K. (1996) Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur. J. Clin. Pharmacol. 51: 73-78
21. Kappus, H., Remmer, H. (1975) Irreversible protein binding of [14C]imipramine with rat and human liver microsomes. Biochem. Pharmacol. 24: 1079-1084
22. Kimura, S., Umeno, M., Skoda, R. C., Meyer, U. A., Gonzalez, F. J. (1989) The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am. J. Hum. Genet. 45: 889-904
23. Kobayashi, S., Murray, S., Watson, D., Sesardic, D., Davies, D. S., Boobis, A. R. (1989) The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man. Biochem. Pharmacol. 38: 2795-2799
24. Kobayashi, K., Ishizuka, T., Shimada, N., Yoshimura, Y., Kamijma, K., Chiba, K. (1999) Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro. Drug Metab. Dispos. 27: 763-766
25. Kupfenberg, H., Burkhalter, A., Way, E. L. (1964) A sensitive fluorometric assay for morphine in plasma and brain. J. Pharmacol. Exp. Ther. 145: 247-251
26. Margolis, J. M., O'Donnell, J. P., Mankowski, D. C., Ekins, S., Obach, R. S. (2000) (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab. Dispos. 28: 1187-1191
27. Martinez, C., Agundez, J. A. G., Gervasini, G., Martin, R., Benitez, J. (1997) Tryptamine: a possible endogenous substrate for CYP2D6. Pharmacogenetics 7: 85-93
28. Masubuchi, Y., Takahashii, C., Fujio, N., Horie, T., Suzuki, T., Imaoka, S., Funae, Y., Narimatsu S. (1995) Inhibition and induction of cytochrome P450 isoenzymes after repetitive administration of imipramine in rats. Drug Metab. Dispos. 23: 999-1003
29. Masubuchi, Y., Igarashi, S., Suzuki, T., Horiee, T., Narimatsu, S. (1996) Imipramine-induced inactivation of a cytochrome P450 2D enzyme in rat liver microsomes: in relation to covalent binding of its reactive intermediate. J. Pharmacol. Exp. Ther. 279: 724-731
30. Matsunaga, E., Zanger, U. M., Hardwick, J. P., Gelboin, H. V., Meyer, U. A., Gonzales, F. J. (1989) The CYP2D gene subfamily: analysis of the molecular basis of the debrisoquine 4-hydroxylase deficiency in DA rats. Biochemistry 28: 7349-7355
31. Matsunaga, E., Umeno, M., Gonzalez, F. J. (1990) The rat debrisoquine 4-hydroxylase CYP2D gene subfamily: complete sequences of four closely linked genes and evidence that gene conversions maintained sequence homogeneity at the heme binding region of the cytochrome P450 active site. J. Mol. Evol. 30: 155-169
32. McNeil, C. M., Murray, M. (1996) Inhibition of microsomal cytochromes P450 in rat liver by the tricycle antidepressant drug desipramine and its primary oxidized metabolites. Biochem. Pharmacol. 51; 15-20
33. Miksys, S., Rao, Y., Sellers, E. M., Kwan, M., Mendis, D., Tyndale, R. F. (2000) Regional and cellular distribution of CYP2D subfamily members in rat brain. Xenobiotica 30: 547-564
34. Murray, M., Field, S. L. (1992) Inhibition and metabolite complexation of rat hepatic microsomal cytochrome P450 by tricyclic antidepressants. Biochem. Pharmacol. 43: 2065-2071
35. Ohta, S., Tachikava, Y., Makino, Y., Tasaki, Y., Hirobe M. (1990) Metabolism and brain accumulation of tetrahydroisoquinoline (TIQ), a possible parkinsonian inducing substance, in an animal model of a poor debrisoquine metabolizer. Life Sci. 46: 599-605
36. Ring, B. J., Eckstein, J. A., Gillespie, J. S., Binkley, S.N., Vandenbranden, M., Wrighton, S. A. (2001) Identification of the human cytochromes P450 responsible for in vitro formation of R- and S-norfluoxetine. J. Pharmacol. Exp. Ther. 297: 1044-1050
37. Schmider, J., Greenblatt, D. J., von Moltke, L. L., Harmatz, J. S., Shader, R. I. (1996) Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation. Br. J. Clin. Pharmacol. 41: 339-343
38. Schulz-Utermoehl, T., Bennett, A. J., Ellis, S. W., Tucker, G. T., Boobis, A. R., Edwards, R. J. (1999) Polymorphic debrisoquine 4-hydroxylase activity in the rat is due to differences in CYP2D2 expression. Pharmacogenetics 9: 357-366
39. Siegle, I., Fritz, R., Eckhardt, K., Zanger, U. M., Eichelbaum, M. (2001) Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics 11: 237-245
40. Steiner, E., Dumond E., Spina, E., Dahlqvist, R. (1988) Inhibition of desipramine 2-hydroxylation by quinidine and quinine. Clin. Pharmacol. Ther. 43: 577-581
41. Störmer, E., von Moltke, L. L., Schader, R. I., Greenblatt, D. J. (2000) Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab. Dispos. 28: 1168-1175
42. Syrek, M., Wójcikowski, J., Daniel, W. A. (1997) Promazine pharmacokinetics during concurrent treatment with tricyclic antidepressants. Pol. J. Pharmacol. 51: 453-462
43. Tyndale, R. F., Li, Y., Li, N.-Y., Messina, E., Miksys, S., Sellers, E. M. (1999) Characterization of cytochrome P-450 2D1 activity in rat brain: high-affinity kinetics for dextromethorphan. Drug Metab. Dispos. 27: 924-930
44. Wan J., Imaoka, S., Chow, T., Hiroi, T., Yabusaki, Y., Funae, Y. (1998) Expression of four rat CYP2D isoforms in Saccharomyces cerevisiae and their catalytic specificity. Arch. Biochem. Biophys. 348: 383-390
45. Yamamoto, Y., Tasaki, T., Nakamura, A., Iawata, H., Kazusaka, A., Gonzalez, F.J., Fujita, S. (1998) Molecular basis of the Dark Agouti rat drug oxidation polymorphism: importance of CYP2D1 and CYP2D2. Pharmacogenetics 8: 73-82